Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclin-dependent kinase 1–Cyclin B complex, historically known as the Maturation-Promoting Factor (MPF), is a master regulator of the eukaryotic cell cycle, specifically governing the transition from G2 phase into mitosis (StatPearls, PMID: 30855847). The complex consists of the catalytic subunit CDK1 and its regulatory partner, Cyclin B (primarily Cyclin B1), which together phosphorylate a wide array of substrates necessary for nuclear envelope breakdown, spindle assembly, and chromosome condensation (UniProt, P06493; UniProt, P14635). In many human cancers, the CDK1–Cyclin B complex is frequently overexpressed or hyperactivated, driving uncontrolled cell division and contributing to genomic instability (PubMed, 26003166). Consequently, it has been a significant target for oncology drug development, with several small-molecule inhibitors like Dinaciclib and Alvocidib designed to compete with ATP binding at the CDK1 active site (PubChem, CID 46926350). While early pan-CDK inhibitors faced challenges due to narrow therapeutic windows and off-target toxicities such as neutropenia, newer generations of inhibitors are being evaluated in combination therapies to improve efficacy (PubMed, 30634354). Monitoring biomarkers such as Cyclin B1 expression and phospho-histone H3 levels is often employed to assess the pharmacodynamic impact of these therapeutic agents in clinical settings (PubMed, 22496214).
ATP-competitive inhibition of the CDK1 catalytic subunit, preventing the phosphorylation of mitotic substrates and inducing cell cycle arrest at the G2/M phase.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin-dependent kinase 1–Cyclin B complex (CDK1–CCNB) (CDK1–CCNB).